Pharma Convenes At Annual BioClinica Global User Conference

Event Highlights Insight-Based Analytics Tools Advancing Clinical Trials

May 18, 2015, 12:59 ET from BioClinica, Inc.

NEWTOWN, Pa., May 18, 2015 /PRNewswire/ -- BioClinica®, Inc., a leading specialty clinical trials services and technology provider, today announced that pharmaceutical professionals from across a wide range of backgrounds convened at its Fifth Annual Global User Conference, exchanging experiences and successes using insight-based analytics tools to advance clinical trials. The event, held on May 5-6 in the greater Orlando, Florida area, brought together an international group that shared lessons learned, best practices and success stories using BioClinica technologies.

Attendees heard from more than 20 speakers representing a mix of pharmaceutical and biotechnology companies, CROs, industry consultants and technology partners as well as representatives of MedDRA and TransCelerate BioPharma.

"There was a tremendous exchange of ideas with successful collaborative partnering a common theme throughout the meeting," BioClinica President of eClinical Solutions Mukhtar Ahmed said. Sanofi; Johnson & Johnson; Vistakon; Biosense Webster; Cognizant; Catalent; Ultragenyx; C.R. Bard; Seattle Genetics; and NextDocs were among those who presented or participated in expert panel discussions covering more than 30 sessions. "These innovative organizations showed the many different ways they are using the intelligence of the data built on BioClinica technology to run better clinical trials."

Mark Travers, PhD, Merck's executive director and global head of monitoring excellence, delivered the keynote address on the changing role of clinical trial monitoring. "Quality by Design methodology combined with new technology creates a platform to introduce smart monitoring in clinical trials for greater success," Dr. Travers said. "Today's technology gives us the ability to look at the data across multiple systems and sites so we're able to predict what might happen in areas like site performance and recruitment. This creates opportunities to achieve greater control over critical factors protective of patients, data integrity and the study protocol."

An expert panel discussion on risk-based monitoring led by BioClinica's Vice President of Clinical Innovation, Courtney McBean, underscored Dr. Travers' presentation and an intelligent monitoring approach.

McBean, co-developer of Compass explained, "Risk-based approaches enable study teams to detect and even predict potential problem areas by looking at what's trending on a regular basis. This allows the proper steps to be taken to ensure study sites receive the support needed to be successful."  

The conference also served as a forum for BioClinica product engineers and expert professional services team to stay connected to customers' emerging needs and trends shaping the future of clinical trials. "We thank everyone who participated and look forward to bringing everyone together again next year," Ahmed said.  

Other upcoming events featuring BioClinica experts include:

Follow BioClinica on the Trial Blazers blog at and on Twitter at

About BioClinica, Inc.
BioClinica is a specialty clinical trials services provider that improves the development of new medical therapies by delivering expertise and technologies that enhance clinical research data and analytics, worldwide. The company offers industry-leading medical imaging services, enterprise eClinical technologies, clinical research centers and cardiovascular safety solutions that bring quality and efficiency to every phase of clinical development. BioClinica's experience spans three decades and includes thousands of studies in all therapeutic areas. The company serves more than 400 pharmaceutical, biotechnology, and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia. For more information, please visit

Logo -

SOURCE BioClinica, Inc.